Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

Phase 1

Completed

Conditions: CLASSICAL HODGKIN LYMPHOMA

Interventions: Drug: Brentuximab Vedotin
Drug: Etoposide
Drug: Soludomerin
Drug: Cisplatin
Drug: Ara C

First Posted Date: 2014-09-18

Last Posted Date: 2019-04-24

Lead Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Target Recruit Count: 67

Registration Number: NCT02243436

Locations: 🇪🇸
Hospital General Universitario Gregorio Marañon, Madrid, Spain
🇪🇸
Hospital Clínico de Valencia, Valencia, Spain
🇪🇸
Hospital Universitario Ramón y Cajal, Madrid, Spain

and more 11 locations

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Phase 1

Withdrawn

Conditions: Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease
Primary Effusion Lymphoma

Interventions: Drug: Pomalidomide
Drug: Rituximab
Drug: Prednisone
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide

First Posted Date: 2014-08-29

Last Posted Date: 2018-08-31

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02228512

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent Hodgkin Lymphoma
Refractory Hodgkin Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis

First Posted Date: 2014-08-28

Last Posted Date: 2024-02-15

Lead Sponsor: University of Washington

Target Recruit Count: 45

Registration Number: NCT02227199

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1

Completed

Conditions: CD20 Positive
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Ibrutinib
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Rituximab

First Posted Date: 2014-08-19

Last Posted Date: 2018-01-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT02219737

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1

Active, not recruiting

Conditions: Adult Grade III Lymphomatoid Granulomatosis
B-cell Chronic Lymphocytic Leukemia
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Grade 2 Follicular Lymphoma
Contiguous Stage II Grade 3 Follicular Lymphoma
Contiguous Stage II Mantle Cell Lymphoma

Interventions: Drug: lenalidomide
Drug: etoposide
Drug: prednisone
Drug: vincristine sulfate
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: rituximab
Other: quality-of-life assessment
Other: laboratory biomarker analysis

First Posted Date: 2014-08-12

Last Posted Date: 2023-04-28

Lead Sponsor: University of Chicago

Target Recruit Count: 46

Registration Number: NCT02213913

Locations: 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸
Illinois Cancer Care, Peoria, Illinois, United States

and more 3 locations

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Recurrent Burkitt Lymphoma
Refractory Acute Lymphoblastic Leukemia
AIDS-Related Burkitt Lymphoma
Atypical Burkitt/Burkitt-Like Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Recurrent Acute Lymphoblastic Leukemia
Refractory Burkitt Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Biological: Ofatumumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2014-07-24

Last Posted Date: 2024-06-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT02199184

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Extensive Stage Small Cell Lung Cancer

Interventions: Drug: BKM120
Drug: cisplatin
Drug: etoposide

First Posted Date: 2014-07-18

Last Posted Date: 2018-01-09

Lead Sponsor: University of California, Davis

Target Recruit Count: 3

Registration Number: NCT02194049

Locations: 🇺🇸
University of California at Davis Cancer Center, Sacramento, California, United States

Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)

Phase 2

Conditions: Small Cell Lung Cancer Extensive Stage

Interventions: Drug: Etoposide

First Posted Date: 2014-07-02

Last Posted Date: 2014-09-12

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 210

Registration Number: NCT02179528

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Phase 3

Active, not recruiting

Conditions: Ganglioneuroblastoma
Localized Resectable Neuroblastoma
Neuroblastoma
Localized Unresectable Neuroblastoma

Interventions: Other: Clinical Observation
Procedure: Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Bone Marrow Biopsy
Procedure: Ultrasound
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide

First Posted Date: 2014-06-27

Last Posted Date: 2024-11-01

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 621

Registration Number: NCT02176967

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 219 locations

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Phase 3

Active, not recruiting

Conditions: Ann Arbor Stage IIIB Hodgkin Lymphoma
Childhood Hodgkin Lymphoma
Ann Arbor Stage IVB Hodgkin Lymphoma
Classic Hodgkin Lymphoma
Ann Arbor Stage IIB Hodgkin Lymphoma
Ann Arbor Stage IVA Hodgkin Lymphoma

Interventions: Biological: Bleomycin Sulfate
Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Methylprednisolone
Other: Pharmacological Study
Drug: Prednisone
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Vincristine Sulfate

First Posted Date: 2014-06-18

Last Posted Date: 2024-12-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 600

Registration Number: NCT02166463

Locations: 🇺🇸
Bronson Methodist Hospital, Kalamazoo, Michigan, United States
🇺🇸
Corewell Health Children's, Royal Oak, Michigan, United States
🇺🇸
Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States

and more 196 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy